drugset / Trial / NCT01458028

Age and Gender Effects on the Pharmacokinetics of BAY85-3934

NCT01458028

Phase 1 Completed 48 enrolled Bayer
RandomizedParallel-groupDouble-blindBasic science

Summary

Single dose study of BAY85-3934 compared to placebo in young/elderly male and female healthy subjects. The main focus of the study is to determine if the pharmacokinetics (drug levels in blood) of BAY85-3934 is similar or not in the four subject groups. Qualifying subjects will be dosed with a single tablet of BAY85-3934 (or placebo) and blood will be drawn over 4 days. The safety and tolerability of BAY85-3934 compared to placebo will also be evaluated over the 5 days of the study.

Timeline

Start
2011-09
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Molidustat Small molecule 20 mg

Indications